Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
News Briefing channel feed
Novartis, Gilead, GSK grab positive CHMPs; Menarini and Radius sign up to $350M partnership
5 years ago
This week's wave of biotech IPO players bumps up offerings and targets bigger harvests of cash
5 years ago
Ayahuasca inspires another biotech startup at ATAI; Mylan TB drug gets green light in India
5 years ago
Pieris slammed with FDA hold; Biogen adds PhIV for Spinraza
5 years ago
BMS gets the ball rolling on liso-cel in Europe; BeiGene files China NDA for in-house PARP drug
5 years ago
Merck KGaA takes its I/O option on F-star Therapeutics; Nephron spends $215M, eyeing spot in Covid-19 vaccine chain
5 years ago
Biohaven recruits a Kardashian to help sell migraine drug; GSK licenses lentiviral tech to Orchard
5 years ago
J&J nabs new OK for IL-23 drug Tremfya; Merck KGaA spinout ups Series A tally to €20.1M
5 years ago
Celsion takes a nosedive as board recommends trial halt; Three biotech IPOs set terms above $90M
5 years ago
AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic
5 years ago
Biopharma companies pledge $1B to fund antibiotics R&D as field shrivels; Four biotechs hunt $797M+
5 years ago
Zai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics
5 years ago
Boehringer Ingelheim ties the knot with Numab on new antibodies; Cabaletta inks pact with Artisan
5 years ago
Poseida tees $150M IPO; Gilead sends HBV program back to Precision; New HIV data from Merck, Gilead
5 years ago
Biogen bags an AAV gene therapy program from Massachusetts Eye and Ear; Biotechs raised $1B-plus in latest round of follow-ons
5 years ago
Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A; The Carlyle Group bets on Indian CDMO
5 years ago
EMA removes negative note on label of PTC's Duchenne drug; GSK, Akebia win Japan OK for oral anemia drugs
5 years ago
J&J scuttles PhIII lupus program on failed data analysis; Novartis pays $345M to resolve bribery charges
5 years ago
CRISPR Therapeutics blueprints cell therapy manufacturing site; Regeneron fights back against kickback claims
5 years ago
Biohaven reports another trial failure for troriluzole; Cyclica raises C$23M for AI driven discovery platform
5 years ago
Boehringer Ingelheim to cash out Hikma stake; Breast cancer biotech sets terms for IPO
5 years ago
Looking at a groundbreaking advance, Myovant gets a priority review at FDA; Agenus, G1 forge new China deals
5 years ago
Ultragenyx’s ultra-expensive ultra-rare disease drug earns second nod; Another round of promising NASH data
5 years ago
AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab
5 years ago
First page
Previous page
38
39
40
41
42
43
44
Next page
Last page